Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant ...

Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced initiation of a Phase 1 clinical trial (NCT07414940) evaluating Actinium ...
The Baltimore Sun

Orioles’ Kyle Bradish latest MLB pitcher to try ‘low risk’ PRP injection for UCL sprain

SARASOTA, Fla. — As the number of elbow injuries for MLB pitchers has risen over the last few decades, so has the urgency in the medical community to find ways to hasten the recovery process and allow ...
Pharmabiz

Blue Earth Therapeutics and University College London initiate phase 1 trial evaluating Actinium (225Ac) rhPSMA-10.1 injection in mCRPC

Blue Earth Therapeutics and University College London initiate phase 1 trial evaluating Actinium (225Ac) rhPSMA-10.1 injection in mCRPC: Oxford, UK Saturday, July 11, 2026, 16:00 ...